Table 1. Patients' characteristics in the two Groups receiving Prolutex or Cyclogest
Variable Level Total Treatment p
Prolutex Cyclogest
Age 20-25
25.1-30
30.1-35
35.1-40
24 (12.2%)
50 (25.4%)
53 (26.9%)
70 (35.5%)
13 (13.4%)
32 (33.0%)
17 (17.5%)
35 (36.1%)
11 (11.0%)
18 (18.0%)
36 (36.0%)
35 (35.0%)
0.238
BMI 16-20
20.1-25
25.1-30
>30.1
13 (6.6%)
108 (54.8%)
57 (28.9%)
19 (9.6%)
9 (9.3%)
63 (64.9%)
21 (21.6%)
4 (4.1%)
4 (4.0%)
45 (45.0%)
36 (36.0%)
15 (15.0%)
<0.001
AFC     11.87±5.97 11.77±6.82 0.912
Infertility (Type) Primary
Secondary
146 (74.1%)
51 (25.9%)
79 (81.4%)
18 (18.6%)
67 (67.0%)
33 (33.0%)
0.021*
Infertility (Cause) Male factor
PCOS
Age factor
Uterine factor
Tubual factor
Mixed
Other
60 (30.5%)
10 (5.1%)
9 (4.6%)
3 (1.5%)
21 (10.7%)
66 (33.5%)
28 (14.2%)
29 (29.9%)
5 (5.2%)
3 (3.1%)
3 (3.1%)
9 (9.3%)
30 (30.9%)
18 (18.6%)
31 (31.0%)
5 (5.0%)
6 (6.0%)
0 (0.0%)
12 (12.0%)
36 (36.0%)
10 (10.0%)
0.327**
Chemical Pregnancy No chemical pregnancy
Chemical pregnancy
115 (58.4%)
82 (41.6%)
57 (58.8%)
40 (41.2%)
58 (58.0%)
42 (42.0%)
0.914*

Based on Mann-Whitney test.
* Based on Chi-Square test.
** Based on Fisher exact test.